# Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients

> **NCT02767557** · PHASE2 · COMPLETED · sponsor: **Herlev Hospital** · enrollment: 147 (actual)

## Conditions studied

- Unresectable Pancreatic Carcinoma

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Gemcitabine
- **DRUG:** nab-Paclitaxel

## Key facts

- **NCT ID:** NCT02767557
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-26
- **Primary completion:** 2021-08-12
- **Final completion:** 2023-01-01
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2023-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02767557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02767557, "Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02767557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*